Clinical Trial Update: Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma

View source ↗

Summary

The clinical trial update reports relapse-free survival results for adjuvant dabrafenib/trametinib in patients with BRAF V600-mutated stage III/IV melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Novartis | Conditions: BRAF V600 Mutated-Stage III/IV Melanoma | Status: COMPLETED